Autolus
215 Euston Road
London
NW1 2BE
United Kingdom
Website: http://www.autolus.com/
Email: contact@autolus.com
77 articles about Autolus
-
Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%.
-
Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
-
Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022
5/2/2022
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the presentation of three novel cell programming approaches at the American Society of Gene & Cell Therapy being held May 16-19, 2022.
-
Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5
4/25/2022
Autolus Therapeutics plc today announced that it will release its first quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, May 5, 2022.
-
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
3/31/2022
Autolus Therapeutics plc today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus’ leading CAR T clinical candidate, Orphan Medical Product Designation for treatment of acute lymphoblastic leukemia (ALL) patients.
-
Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology
3/3/2022
Autolus Therapeutics plc today announced the publication of an article in BioTechniques describing a novel technology that provides for very low levels of expression of one gene module, while maintaining high levels of expression of other gene modules expressed from the same promotor1.
-
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10
2/21/2022
Autolus Therapeutics plc today announced that it will release its fourth quarter and full year 2021 financial results and operational highlights before open of U.S. markets on Thursday, March 10, 2022.
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Autolus Therapeutics to Present at Conferences During January 2022
1/5/2022
Autolus Therapeutics plc today announced that they are scheduled to deliver a corporate presentation at the following virtual conferences: Dr. Christian Itin, Chief Executive Officer, will present at the 40th annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 8.15 am ET.
-
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
12/13/2021
Autolus Therapeutics plc presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled “Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process” at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021.
-
Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition
12/6/2021
Autolus Therapeutics plc today announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021.
-
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
11/15/2021
Autolus Therapeutics plc today announced that Dr. William D. Young, a Senior Advisor to Blackstone Life Sciences, has been appointed as a non-executive director to its board of directors, effective immediately.
-
Autolus is currently working on advancing obecabtagene autoleucel, its CD19 CAR T cell investigational therapy product candidate, in addition to other applications of obe-cel in B-cell malignancies.
-
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
9/15/2021
Autolus Therapeutics plc today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021.
-
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
9/1/2021
Autolus Therapeutics plc today announced publication of the obecabtagene autoleucel (obe-cel) Phase 1 ALLCAR19 data in Journal of Clinical Oncology 1
-
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
8/9/2021
Autolus Therapeutics plc announced that it has received Promising Innovative Medicine designation from the UK Medicines and Healthcare products Regulatory Agency for AUTO1, the company’s CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed/refractory adult B-cell Acute Lymphocytic Leukemia in patients 18 years and older.
-
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress
8/5/2021
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its operational and financial results for the quarter ended June 30, 2021.
-
Shares of Autolus were up more than 12% this morning after it forged an exclusive licensing agreement with Moderna to develop new messenger RNA therapeutics for cancer.
-
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
7/8/2021
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.
-
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
6/15/2021
Autolus Therapeutics plc announced that it has received innovative licensing and access pathway designation from the UK Medicines and Healthcare products Regulatory Agency for AUTO1, the company’s CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory adult B-cell Acute Lymphocytic Leukemia in patients 18 years and older.